Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  incomplete Freund's adjuvant
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 114 for your search:
Start Over
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02897, CDR0000066963, 99-C-0051, T98-0085, CCCGHS-NCI-T98-0085, NCI-T98-0085, NCI-99-C-0051B, NCT00019682
Vaccine Therapy and/or Sargramostim in Treating Patients With Locally Advanced or Metastatic Melanoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067568, U10CA021115, ECOG-4697, SWOG-E4697, E4697, NCT00005034
Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-2012-03086, DM 97-325, MDA-DM-97325, NCI-T98-0017, T98-0017, NCT00004918
Vaccine Therapy in Treating Patients With Liver Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: CDR0000067782, P30CA016042, UCLA-9905003, NCI-H00-0053, NCT00005629
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 10464, UVACC-MEL-41, UVACC-28502, UVACC-HIC-10464, NCT00089219
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000430929, UVACC-HIC-11491, UVACC-34104, UVACC-MEL-44, UVACC-GCRC-CLS013, UVACC-HITC-02620, MDA-2005-0070, Mel 44, NCT00118274
Immunization With 8 Peptides Mixed With Adjuvant Montanide ISA 51 in HLA-A2 Patients With Metastatic Cutaneous Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2003-007, NCT00145158
Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 12095B, NCT00203892
Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 20 to 80
Sponsor: Other
Protocol IDs: FPCR1R2-2, NCT00655785
Novel Peptide Vaccination for Patients With Advanced Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 20 to 85
Sponsor: Other
Protocol IDs: IMU-H21-40-P?/?, NCT01225471
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 29810, NCT01312389
Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, NIH WGMCC
Protocol IDs: 030162, 03-C-0162, NCI-5855, CDR0000304438, NCT00062036
Phase II Pilot Study of HER2-Neu Peptide Vaccine in Patients with Recurrent Metastatic Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-97-C-0118, NCI-T97-0009, T97-0009
Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000065915, NCI-98-C-0022, NCI-T97-0088, T97-0088, NCT00019383
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: CDR0000065997, NCI-98-C-0040, NCI-T97-0092, T97-0092, NCT00019396
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 79
Sponsor: NCI, Other
Protocol IDs: 7621, IRB-HSR 7621, NCI-G98-1389, UVACC-HIC-7621, UVA-HIC-7621, NCT00003222
Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066176 (10M-97-1), LAC-USC-10M971, LAC-USC-FDR001101, NCI-T97-0100, T97-0100, NCT00003274
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000066287, NCI-98-C-0095, NCI-T98-0012, T98-0012, NCT00019487
Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066310 (10M-97-3), LAC-USC-10M973, NCI-G98-1432, NCI-T97-0099, T97-0099, NCT00003339
Phase II Study of Immunization With gp100 Antigen With Endoplasmic Reticulum Insertion Signal Sequence Alone or in Combination With Interleukin-2 in Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-98-C-0142, NCI-T98-0036, T98-0036
Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 980139, 98-C-0139, NCI-98-C-0139, NCI-T97-0081, T97-0081, NCT00019526, NCT00001703
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000067051, NCI-99-C-0092, NCI-T99-0033, T99-0033, NCT00019721
Start Over